THE TAKEDA ONCOLOGY Here2Assist™ PROGRAM

The Takeda Oncology Here2Assist Program is a comprehensive support program committed to helping patients throughout their therapy.


 

  • ACCESS SUPPORT: Takeda Oncology Here2Assist Program case managers may provide access support for patients prescribed Takeda Oncology medications.
  • FINANCIAL ASSISTANCE: The Takeda Oncology Here2Assist Program can help identify financial assistance programs that may be able to help your patients with the cost of their treatment.

    To learn more about the Takeda Oncology Co-Pay Assistance Program, please visit www.TakedaOncologyCoPay.com or call 1-844-817-6468.
  • HELPFUL RESOURCES: Takeda Oncology Here2Assist Program case managers can provide your patients with information about additional resources that may assist with the day-to-day support they need.

 

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

Takeda Oncology makes no representation as to the accuracy of the information contained on sites we do not own or control. Takeda Oncology does not recommend and does not endorse the content on any third-party websites. Your use of third-party websites is at your own risk and subject to the terms and conditions of use for such sites.

Cancel Continue >
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib) and entering one that is not owned or controlled by Takeda Oncology.

This link will take you to the corporate ARIAD Pharmaceuticals, Inc. website.

Cancel Continue >
Close

You are now leaving ALUNBRIG.com, the official site for ALUNBRIG® (brigatinib).

This link will take you to another Takeda Oncology website.

Cancel Continue >
Close

The site you are about to enter is intended for US healthcare professionals only.

Please confirm that you are a US healthcare professional.

Yes, I confirm that I am a US healthcare professional Cancel
Close

In Vitro: ALUNBRIG Inhibited 17
ALK-Inhibitor-Resistant Mutations1,2

ALUNBRIG exhibited in vivo antitumor activity against 4 mutant forms of EML4-ALK, including the G1202R and L1196M mutants identified in NSCLC tumors in patients who had progressed on crizotinib.

 

We use cookies to gather web statistics that help us improve our site. We store no personal details.
ACCEPT

Read More